Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Standard
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. / Kröger, Nicolaus; Panagiota, Victoria; Badbaran, Anita; Zabelina, Tatiana; Triviai, Ioanna; Araujo Cruz, Michelle Maria; Shahswar, Rabia; Ayuketang, Francis Ayuk; Gehlhaar, Marten; Wolschke, Christine; Bollin, Robin; Walter, Carolin; Dugas, Martin; Wiehlmann, Lutz; Lehmann, Ulrich; Koenecke, Christian; Chaturvedi, Anuhar; Alchalby, Haefaa; Stadler, Michael; Eder, Matthias; Christopeit, Maximilian; Göhring, Gudrun; Koenigsmann, Michael; Schlegelberger, Brigitte; Kreipe, Hans-Heinrich; Ganser, Arnold; Stocking, Carol ; Fehse, Boris; Thol, Felicitas; Heuser, Michael.
in: BIOL BLOOD MARROW TR, Jahrgang 23, Nr. 7, 07.2017, S. 1095-1101.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
AU - Kröger, Nicolaus
AU - Panagiota, Victoria
AU - Badbaran, Anita
AU - Zabelina, Tatiana
AU - Triviai, Ioanna
AU - Araujo Cruz, Michelle Maria
AU - Shahswar, Rabia
AU - Ayuketang, Francis Ayuk
AU - Gehlhaar, Marten
AU - Wolschke, Christine
AU - Bollin, Robin
AU - Walter, Carolin
AU - Dugas, Martin
AU - Wiehlmann, Lutz
AU - Lehmann, Ulrich
AU - Koenecke, Christian
AU - Chaturvedi, Anuhar
AU - Alchalby, Haefaa
AU - Stadler, Michael
AU - Eder, Matthias
AU - Christopeit, Maximilian
AU - Göhring, Gudrun
AU - Koenigsmann, Michael
AU - Schlegelberger, Brigitte
AU - Kreipe, Hans-Heinrich
AU - Ganser, Arnold
AU - Stocking, Carol
AU - Fehse, Boris
AU - Thol, Felicitas
AU - Heuser, Michael
N1 - Copyright © 2017. Published by Elsevier Inc.
PY - 2017/7
Y1 - 2017/7
N2 - Molecular genetics may influence outcome for patients with myelofibrosis. To determine the impact of molecular genetics on outcome after allogeneic stem cell transplantation, we screened 169 patients with primary myelofibrosis (n = 110), post-ET/PV myelofibrosis (n = 46), and myelofibrosis in transformation (n = 13) for mutations in 16 frequently mutated genes. The most frequent mutation was JAK2V617F (n = 101) followed by ASXL1 (n = 49), calreticulin (n = 34), SRSF2 (n = 16), TET2 (n = 10), U2AF1 (n = 11), EZH2 (n = 7), MPL (n = 6), IDH2 (n = 5), IDH1 (n = 4), and CBL (n = 1). The cumulative incidence of non-relapse mortality (NRM) at 1 year was 21% and of relapse at 5 years 25%. The 5-year progression-free and overall survival (PFS and OS) was 52% and 56%, respectively. In a multivariate analysis CALR mutation was an independent factor for lower NRM (hazard ratio (HR) 0.415, p = 0.05), improved PFS (HR 0.393, p = 0.01), and OS (HR 0.448, p = 0.03). ASXL1 and IDH2 mutations were independent risk factors for lower PFS (HR 1.53, p = 0.008 and HR 5.451, p = 0.002, respectively), while no impact was observed for "triple negative" patients. Molecular genetics, especially CALR, IDH2, and ASXL1 mutations, may thus be useful to predict outcome independently from known clinical risk factors after allogeneic stem cell transplantation for myelofibrosis.
AB - Molecular genetics may influence outcome for patients with myelofibrosis. To determine the impact of molecular genetics on outcome after allogeneic stem cell transplantation, we screened 169 patients with primary myelofibrosis (n = 110), post-ET/PV myelofibrosis (n = 46), and myelofibrosis in transformation (n = 13) for mutations in 16 frequently mutated genes. The most frequent mutation was JAK2V617F (n = 101) followed by ASXL1 (n = 49), calreticulin (n = 34), SRSF2 (n = 16), TET2 (n = 10), U2AF1 (n = 11), EZH2 (n = 7), MPL (n = 6), IDH2 (n = 5), IDH1 (n = 4), and CBL (n = 1). The cumulative incidence of non-relapse mortality (NRM) at 1 year was 21% and of relapse at 5 years 25%. The 5-year progression-free and overall survival (PFS and OS) was 52% and 56%, respectively. In a multivariate analysis CALR mutation was an independent factor for lower NRM (hazard ratio (HR) 0.415, p = 0.05), improved PFS (HR 0.393, p = 0.01), and OS (HR 0.448, p = 0.03). ASXL1 and IDH2 mutations were independent risk factors for lower PFS (HR 1.53, p = 0.008 and HR 5.451, p = 0.002, respectively), while no impact was observed for "triple negative" patients. Molecular genetics, especially CALR, IDH2, and ASXL1 mutations, may thus be useful to predict outcome independently from known clinical risk factors after allogeneic stem cell transplantation for myelofibrosis.
KW - Journal Article
U2 - 10.1016/j.bbmt.2017.03.034
DO - 10.1016/j.bbmt.2017.03.034
M3 - SCORING: Journal article
C2 - 28389256
VL - 23
SP - 1095
EP - 1101
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 7
ER -